RxDoctor Payments DataLook up a doctor →

Joel Solis, MD

Family Medicine · McAllen, TXNPI 1033191424

Payments from drug & device makers

$21,116,647in general payments, 2019–2025

Across 3,489 payments — averaging $6052.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$11M
  • AstraZeneca$3.6M
  • Janssen Research & Development, LLC$1.4M
  • Sanofi US Services Inc.$1.3M
  • Boehringer Ingelheim International GmbH$1.3M
  • AbbVie$1.2M
  • plus $1.4M from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.691$10,995,824
AstraZeneca198$3,557,067
Janssen Research & Development, LLC95$1,406,404
Sanofi US Services Inc.52$1,289,274
Boehringer Ingelheim International GmbH260$1,283,329
AbbVie(2 entities)412$1,158,340
Intercept Pharmaceuticals, Inc.181$465,409
Amgen(2 entities)488$239,611
Romark Laboratories, LC21$236,057
Pfizer59$174,387
Novavax Inc7$81,945
Vivus LLC16$76,676
Radius Health, Inc.41$49,953
Evofem Biosciences, Inc.14$28,337
Sage Therapeutics, LLC10$17,845
Merck23$15,842
Novo Nordisk AS132$10,102
Intercept Pharma Europe Ltd.1$7,611
Lexicon Pharmaceuticals, Inc.4$5,130
Boehringer Ingelheim RCV GmbH & Co KG23$3,433
Novo Nordisk172$2,940
Boehringer Ingelheim34$1,413
Lilly USA, LLC74$971
Johnson & Johnson18$861
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC67$689
Dexcom, Inc.32$555
Amarin Pharma, Inc.42$501
Antares Pharma, Inc.31$485
Sanofi-aventis U.S. LLC24$469
Kowa Pharmaceuticals America, Inc.16$393
E.r. Squibb & Sons, L.L.C.2$346
GSK13$307
Astellas Pharma US Inc15$267
Biohaven Pharmaceutical Holding Company Ltd.20$265
Sumitomo Pharma America, Inc.11$219
Ironwood Pharmaceuticals, Inc12$212
Biohaven Pharmaceuticals, Inc.11$197
Arbor Pharmaceuticals, Inc.16$194
Teva Pharmaceuticals USA, Inc.18$192
Abbott9$185
Alnylam Pharmaceuticals Inc.4$182
Takeda Pharmaceuticals U.S.A., Inc.14$178
Madrigal Pharmaceuticals2$147
Novartis8$136
Otsuka America Pharmaceutical, Inc.6$132
Esperion Therapeutics, Inc.8$127
Bard Peripheral Vascular, Inc.1$122
Paratek Pharmaceuticals, Inc.7$109
Stryker2$105
Genentech USA, Inc.6$103
Mannkind Corporation7$99
Exact Sciences5$96
Eisai Inc.5$89
Phadia US Inc.3$71
Mylan Specialty L.p.4$66
Phathom Pharmaceuticals, Inc.5$61
Intuity Medical Inc3$52
Sanofi Pasteur Inc.3$51
Bayer3$50
Optinose US, Inc.3$50

How this compares

$21,116,647 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$112,726
Medicare patients
352
Services billed
3,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in McAllen

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →